TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10689150

Group type: EXPERIMENTAL
Intervention: Intra-nasal live attenuated influenza vaccine (Livac)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (Ivac)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baculovirus recombinant vaccine or adjuvanted Ivac
Number of subjects: 0
Study: 9337824

Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (no long-term oxygen therapy)
Number of subjects: 135
Study: 8450436

Group type: EXPERIMENTAL
Intervention: PRK with centration measured from the pupillary center
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PRK with centration measured from the corneal vertex
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Right eyes
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Decentration
Number of subjects: 49
Study: 2880596

Group type: EXPERIMENTAL
Intervention: Etintidine 300 mg b.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Etintidine 400 mg b.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Etintidine 300 mg nocte.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Etintidine 600 mg nocte.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg nocte.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Etintidine 300 mg b.d. and 400 mg b.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Etintidine (any dose) at bedtime.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30267093

Group type: EXPERIMENTAL
Intervention: 0.5% proparacaine eye drops (anesthesia trial)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline drops (placebo trial)
Number of subjects: 10
Study: 28033375

Group type: EXPERIMENTAL
Intervention: Uremic solutes concentrations at baseline and after one year of follow-up
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Uremic solutes concentrations
Number of subjects: 80
Study: 24464845

Group type: EXPERIMENTAL
Intervention: Incremental pump speed (testinc) with a mean increase of 1486±775 rpm during exercise testing.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fixed pump speed (testfix) during exercise testing.
Number of subjects: 14
Study: 23322144

Group type: EXPERIMENTAL
Intervention: Donepezil 23 mg/day
Number of subjects: 5400000

Group type: COMPARATOR
Intervention: Donepezil 10 mg/day
Number of subjects: 5400000
Study: 20438292

Group type: EXPERIMENTAL
Intervention: recombinant human BNP (rhBNP)
Number of subjects: 149

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 149
Study: 17388755

Group type: EXPERIMENTAL
Intervention: Biphasic inhalation profiles with low flow segments of 300 mL to 900 mL inhaled volume at 8 L/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biphasic inhalation profiles
Number of subjects: 0
Study: 15516367

Group type: EXPERIMENTAL
Intervention: NaHCO(3) ingestion (3 mmol/kg body weight)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control study (no NaHCO(3) ingestion)
Number of subjects: 7
Study: 12042887

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment for 12 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 23
Study: 9527357

Group type: EXPERIMENTAL
Intervention: Chlorhexidine/thymol-containing varnish (Cervitec) applied twice within 3 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo varnish without active ingredients
Number of subjects: 25
Study: 8583450

Group type: EXPERIMENTAL
Intervention: Wound drainage
Number of subjects: 177

Group type: COMPARATOR
Intervention: No wound drainage
Number of subjects: 177
Study: 2378441

Group type: EXPERIMENTAL
Intervention: Terbutaline (Bricanyl) 0.5 mg t.i.d. via Turbuhaler
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fenoterol (Berotec) 0.2 mg t.i.d. via Inhalator Ingelheim
Number of subjects: 36
Study: 1092727

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg/day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Aspirin (3.6 Gm/day)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Naproxen (250 mg twice daily)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 119

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 119
Study: 30500067

Group type: EXPERIMENTAL
Intervention: SCP care
Number of subjects: 225
Study: 28292223

Group type: EXPERIMENTAL
Intervention: Virtual-reality job interview training (VR‐JIT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Completion of virtual interviews
Number of subjects: 79
Study: 25437827

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196
Study: 24053114

Group type: EXPERIMENTAL
Intervention: Teledentistry examination
Number of subjects: 291

Group type: COMPARATOR
Intervention: Traditional visual tactile examination
Number of subjects: 291
Study: 21482368

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vaginal dinoprostone
Number of subjects: 200
Study: 17938939

Group type: EXPERIMENTAL
Intervention: Cholestyramine with biofeedback therapy (group A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Biofeedback therapy alone (group B)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 21
Study: 16257388

Group type: EXPERIMENTAL
Intervention: High personal standards condition (n = 18)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low personal standards condition (n = 23)
Number of subjects: 41
Study: 12620169

Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine and 0.3% nifedipine applied twice daily for 6 weeks
Number of subjects: 0
Study: 10964191

Group type: EXPERIMENTAL
Intervention: Training in relaxation, cognitive restructuring, and communication skills; Duration: Immediate training.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group with training delayed for 6 months.
Number of subjects: 61
Study: 8626984

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Dermatophagoides extract
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 88
Study: 1370507

Group type: EXPERIMENTAL
Intervention: Detirelix 1 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Detirelix 5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Detirelix 20 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Detirelix 5 mg and 20 mg
Number of subjects: 6
Study: 6707342

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (20 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both nifedipine and isosorbide dinitrate
Number of subjects: 19

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 19
Study: 28704314

Group type: EXPERIMENTAL
Intervention: Visual feedback during barbell back squat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no visual feedback)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 0
Study: 29161930

Group type: EXPERIMENTAL
Intervention: Patient-specific positioning guides (PSPGs)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 109
Study: 26509816

Group type: EXPERIMENTAL
Intervention: Intermittent weaning pattern
Number of subjects: 145

Group type: COMPARATOR
Intervention: Steady weaning pattern
Number of subjects: 145
Study: 24281893

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium Citrate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of Caffeine and Sodium Citrate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 22862827

Group type: EXPERIMENTAL
Intervention: Aprepitant 40 mg
Number of subjects: 176

Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 176
Study: 20702609

Group type: EXPERIMENTAL
Intervention: 75 μg I/d supplementation
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 150 μg I/d supplementation
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: COMPARATOR
Intervention: Unsupplemented women
Number of subjects: 109
Study: 16583464

Group type: EXPERIMENTAL
Intervention: LD-rofecoxib (0.3 mg/kg/day up to 12.5 mg/day)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: HD-rofecoxib (0.6 mg/kg/day up to 25 mg/day)
Number of subjects: 310

Group type: COMPARATOR
Intervention: naproxen (15 mg/kg/day)
Number of subjects: 310
Study: 12664078

Group type: EXPERIMENTAL
Intervention: GLP‐2 infusion (25 pmol/kg body weight) for 4.5 hours
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 18
Study: 11105737

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 9169336

Group type: EXPERIMENTAL
Intervention: UVB plus calcipotriene 0.005% ointment twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: UVB plus mineral oil
Number of subjects: 20
Study: 1414449

Group type: EXPERIMENTAL
Intervention: Intervention group viewed a 6-minute videotape explaining reasons to wear seat belts.
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group viewed a videotape espousing general preventive health care guidelines with no mention of seat belts.
Number of subjects: 326
Study: 3886302

Group type: EXPERIMENTAL
Intervention: 200 mg mecillinam daily for 14 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30554092

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and vitamin E co-supplementation (1000 mg/day of omega-3 from flaxseed oil plus 400 IU/day of vitamin E)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29800375

Group type: EXPERIMENTAL
Intervention: Ketamine (1-2 mg/kg IV bolus, then continuous infusion starting at 5 mcg/kg/min, titrated as needed)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 17
Study: 27780506

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: MoCA
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: MoCA and MMSE
Number of subjects: 230
Study: 24333038

Group type: EXPERIMENTAL
Intervention: Web-based multi-component personalized feedback intervention
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 263
Study: 22345630

Group type: EXPERIMENTAL
Intervention: Multimodal behavioral treatment (MBT)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Triptans
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 76
Study: 19929593

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch with concomitant memantine
Number of subjects: 261

Group type: COMPARATOR
Intervention: Rivastigmine transdermal patch without concomitant memantine
Number of subjects: 261
Study: 17324688

Group type: EXPERIMENTAL
Intervention: Nurse-led home-based case management intervention (NHI)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 121
Study: 16263779

Group type: EXPERIMENTAL
Intervention: Intramuscular corticosteroid injections (40 mg methylprednisolone acetate)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 12883695

Group type: EXPERIMENTAL
Intervention: Fixed dosing of epoetin alpha (10,000 IU)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Weight-based dosing of epoetin alpha (150 IU/kg)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 546
Study: 10898435

Group type: EXPERIMENTAL
Intervention: High-frequency exercise training (10 sessions per week for 6 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Low-frequency exercise training (2 sessions per week for 6 weeks)
Number of subjects: 130
Study: 9182001

Group type: EXPERIMENTAL
Intervention: Endometrial ablation by electrosurgery through a hysteroscopic sheet (9 mm) with glycocol distended media (1.5%)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 342
Study: 1398694

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 30
Study: 2861282

Group type: EXPERIMENTAL
Intervention: Triazolam (TZ) 0.5 to 3.0 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentobarbital (PTB) 100 to 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam (TZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentobarbital (PTB)
Number of subjects: 0
Study: 31785112

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: n-6 polyunsaturated fatty acids (PUFAs)
Number of subjects: 474
Study: 29781596

Group type: EXPERIMENTAL
Intervention: Cycloergometer training (CYC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard exercises)
Number of subjects: 40
Study: 26736023

Group type: EXPERIMENTAL
Intervention: Behavioral Avoidance Test (BAT-Back) for CLBP patients
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Self-report measures for pain, pain-related fear, disability, catastrophizing, and avoidance behavior
Number of subjects: 97

Group type: COMPARATOR
Intervention: Pain-free controls
Number of subjects: 97
Study: 24950708

Group type: EXPERIMENTAL
Intervention: Eban II intervention
Number of subjects: 200
Study: 22804945

Group type: EXPERIMENTAL
Intervention: Rhubarb, montmorillonite powder combined with blood purification
Number of subjects: 39

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 39
Study: 20387081

Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tolvaptan 60 mg
Number of subjects: 18
Study: 18825655

Group type: EXPERIMENTAL
Intervention: Interventions to improve blood pressure control delivered to both patients and providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive quadrature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline and final measurement analysis
Number of subjects: 0
Study: 15942771

Group type: EXPERIMENTAL
Intervention: Moderate hyperoxia (FIO2 = 30%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 16
Study: 12858483

Group type: EXPERIMENTAL
Intervention: Intravaginal Cytotec
Number of subjects: 276

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Cytotec
Number of subjects: 276
Study: 10473885

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) therapy for 5 months
Number of subjects: 8
Study: 8739934

Group type: EXPERIMENTAL
Intervention: Procaine hydrochloride during cardioplegia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Central anastomoses performed during cardiac arrest
Number of subjects: 74
Study: 1929683

Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (both doses)
Number of subjects: 51
Study: 7201757

Group type: EXPERIMENTAL
Intervention: Tobramycin (1 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gentamicin (1 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefazolin (500 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no antibiotic)
Number of subjects: 40
Study: 30907562

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combination of trastuzumab and lapatinib
Number of subjects: 154
Study: 28045953

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPM) 750 mg/m2 body surface area
Number of subjects: 138

Group type: COMPARATOR
Intervention: Methylprednisolone (MP) 1g
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPM)
Number of subjects: 138
Study: 24910962

Group type: EXPERIMENTAL
Intervention: House Officers (HOs)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Faculty
Number of subjects: 173
Study: 23999279

Group type: EXPERIMENTAL
Intervention: MD‐I (physician intervention)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: PT‐I (patient intervention)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: MD‐I and PT‐I
Number of subjects: 574
Study: 21198798

Group type: EXPERIMENTAL
Intervention: PCA cream applied twice daily before UV irradiation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control cream applied twice daily before UV irradiation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PCA cream applied after UV irradiation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control cream applied after UV irradiation
Number of subjects: 21
Study: 18275343

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory exercise training (CET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exercise control groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exercising groups
Number of subjects: 0
Study: 17138300

Group type: EXPERIMENTAL
Intervention: Preterm infant massage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Observation of preterm infants receiving massage
Number of subjects: 40
Study: 14689371

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg for the first two weeks, 80 mg for 5.5 months, and 40 mg for the last two weeks)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Metoprolol (47.5 mg for two weeks, 95 mg for 5.5 months, and 47.5 mg for the last two weeks)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Telmisartan and Metoprolol (both groups)
Number of subjects: 140
Study: 10631628

Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan succinate alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100 mg sumatriptan succinate with 500 mg naproxen
Number of subjects: 12
Study: 9048267

Group type: EXPERIMENTAL
Intervention: β-Blockers (carvedilol and bisoprolol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-Blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future studies (β-blocker Evaluation Survival Trial - BEST)
Number of subjects: 0
Study: 1586070

Group type: EXPERIMENTAL
Intervention: Flow-by CPAP
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Demand-flow CPAP
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Demand-flow CPAP with 5 cm H2O pressure support (DF-PS5)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Continuous-flow CPAP (CF CPAP)
Number of subjects: 9
Study: 3897550

Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Self-control relaxation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 7
Study: 31061026

Group type: EXPERIMENTAL
Intervention: Swedish as native language (SNL)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Other native language (ONL)
Number of subjects: 641
Study: 29775461

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training with at least modest weight loss (≥3%)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Aerobic exercise training without modest weight loss (<3%)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Combined exercise groups
Number of subjects: 163
Study: 27391900

Group type: EXPERIMENTAL
Intervention: 9 months of intermittent anti-tuberculous therapy under DOTS (86 women)
Number of subjects: 175
Study: 25863554

Group type: EXPERIMENTAL
Intervention: Postcard campaign
Number of subjects: 6050

Group type: EXPERIMENTAL
Intervention: Health Information Technology (HIT) system
Number of subjects: 6050

Group type: EXPERIMENTAL
Intervention: Combined HIT and postcard intervention
Number of subjects: 6050
Study: 23661768

Group type: EXPERIMENTAL
Intervention: QoL feedback with standard psychiatric assessment
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard psychiatric assessment
Number of subjects: 124

Group type: COMPARATOR
Intervention: QoL assessment with standard psychiatric assessment
Number of subjects: 124
Study: 21415777

Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin (DP) chemotherapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mitomycin C, vindesine, and cisplatin (MVP) chemotherapy
Number of subjects: 200
Study: 18502229

Group type: EXPERIMENTAL
Intervention: Interactive multimedia food safety education program on a computer kiosk
Number of subjects: 394

Group type: COMPARATOR
Intervention: Food safety pamphlets
Number of subjects: 394
Study: 16553340

Group type: EXPERIMENTAL
Intervention: Needle-locking device technique (group N)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Conventional technique (group C)
Number of subjects: 230
Study: 12882671

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy with 50 mg mitomycin bound to 375 mg carbon adsorbent (MMC‐CH)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (systemic chemotherapy 3 months after operation)
Number of subjects: 124
Study: 11746535

Group type: EXPERIMENTAL
Intervention: Large-volume leukapheresis (LVL)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal-volume leukapheresis (NVL)
Number of subjects: 23
Study: 9563288

Group type: EXPERIMENTAL
Intervention: Partial reinforcement in ADHD children
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ADHD children
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 22
Study: 7995977

Group type: EXPERIMENTAL
Intervention: Alovudine at AUC12s of 50, 100, or 200 ng*h/mL for up to 16 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AUC12 producing a 50% reduction in p24
Number of subjects: 60
Study: 3287892

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1500 mg/d)
Number of subjects: 37
Study: 30825389

Group type: EXPERIMENTAL
Intervention: B12-FAS (delayed arm)
Number of subjects: 161

Group type: COMPARATOR
Intervention: B12-FAS (immediate arm)
Number of subjects: 161